Literature DB >> 2768840

Studies of connective tissue mast cell-mediated cytotoxicity.

M D Tharp1, C Kasper, D Thiele, M R Charley, D A Kennerly, T J Sullivan.   

Abstract

Although mast cells have been implicated in mediating antitumor activity, the kinetics, mechanism(s), and suspectibility of different tumors to mast cell-mediated cytotoxicity have not been defined. Rat connective tissue mast cells (CTMC) of greater than or equal to 99% purity were investigated in vitro and found to express maximal spontaneous cytotoxicity against the mouse fibrosarcoma cell line WEHI-164 (56.0% +/- 2.1 SEM), the ultraviolet B (UVB)-induced, cutaneous fibrosarcoma 5C25 (34.7% +/- 3.4 SEM), and the human renal cell tumor Currie (26.8% +/- 2.0 SEM) at an effector to target (E:T) ratio of 80:1. Kinetic studies of CTMC-mediated cytotoxicity demonstrated significant detectable lysis against these tumors within 8 h, which was maximal by 16 h. Binding experiments showed that CTMC formed conjugates with all three lytic-sensitive targets; however, CTMC also attached to the lytic-resistant target YAC-1, indicating that conjugate formation alone is not sufficient for mast cell-mediated cytotoxicity. At two different concentrations, mast cell granules (MCG) lysed WEHI-164 (36.5% +/- 6.8 SEM) and 5C25 (34.4% +/- 6.9 SEM), but were only slightly cytotoxic (5.7% +/- 2.9 SEM) against Currie. A potential role for tumor necrosis factor-alpha (TNF-alpha) in CTMC-mediated cytotoxicity also was investigated. Polyclonal antibodies to TNF-alpha greatly reduced CTMC and TNF-mediated lysis of WEHI-164, but only partially inhibited CTMC killing of the slightly TNF-sensitive 5C25 tumors, and had no effect on CTMC cytolysis of Currie. Thus, this study demonstrates that CTMC mediate cytotoxicity in vitro by both TNF-associated and TNF-independent mechanisms. We conclude that CTMC are capable of mediating antitumor activity and that this effect may be important for tumor surveillance in the skin and other sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2768840

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Interferons differentially regulate histamine and TNF-alpha in rat intestinal mucosal mast cells.

Authors:  E Y Bissonnette; B Chin; A D Befus
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 3.  Mast cells as sources of cytokines, chemokines, and growth factors.

Authors:  Kaori Mukai; Mindy Tsai; Hirohisa Saito; Stephen J Galli
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

4.  Redundancy or cell-type-specific regulation? Tumour necrosis factor in alveolar macrophages and mast cells.

Authors:  R E Déry; T J Lin; A D Befus; C D Milne; R Moqbel; G Ménard; E Y Bissonnette
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

5.  Early cellular events in evolving cutaneous delayed hypersensitivity in humans.

Authors:  H A Waldorf; L J Walsh; N M Schechter; G F Murphy
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

6.  Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1.

Authors:  L J Walsh; G Trinchieri; H A Waldorf; D Whitaker; G F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

7.  Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.

Authors:  N Nonomura; H Takayama; K Nishimura; D Oka; Y Nakai; M Shiba; A Tsujimura; M Nakayama; K Aozasa; A Okuyama
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

Review 8.  Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Petri T Kovanen; Emir Hadzijusufovic; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; K Frank Austen; Dean D Metcalfe; Stephen J Galli
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.